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Introduction: Several clinical trials are currently evaluating stem cell therapy for patients with critical limb ischemia that have no
other surgical or endovascular options for revascularization.However, these trials are conductedwith different protocols, including
use of different stem cell populations and different injection protocols, providing little means to compare trials and guide therapy.
Accordingly, we developed a murine model of severe ischemia to allowmethodic testing of relevant clinical parameters.
Methods: High femoral artery ligation and total excision of the superficial femoral artery was performed on C57BL/6 mice.
Mononuclear cells (MNCs) were isolated from the bonemarrow of donormice, characterized using fluorescence-activated cell
sorting, and injected (5 105 to 2 106) into the semimembranosus (proximal) or gastrocnemius (distal) muscle. Vascular
and functional outcomesweremeasured using invasiveDoppler imaging, laserDoppler perfusion imaging, and the Tarlov and
ischemia scores. Histologic analysis included quantification of muscle fiber area and number as well as capillary density.
Results: Blood flow and functional outcomes were improved in MNC-treated mice compared with controls over 28 days
(flow: P < .0001; Tarlov: P  .0004; ischemia score: P  .0002). MNC-treated mice also showed greater gastrocnemius
fiber area (P .0053) and increased capillary density (P .0004). Dose–response analysis showed increased angiogenesis
and gastrocnemius fiber area but no changes in macroscopic vascular flow or functional scores. Overall functional
outcomes in mice injected proximally to the ischemic area were similar to mice injected more distally, but muscle flow,
capillary density, and gastrocnemius fiber area were increased (P < .05).
Conclusions: High femoral ligation with complete excision of the superficial femoral artery is a reliable model of severe
hind limb ischemia in C57BL/6 mice that shows a response to MNC treatment for functional and vascular outcomes. A
dose response to the injection of MNCs appears to be present, at least microscopically, suggesting that an optimal cell
number for stem cell therapy exists and that preclinical testing needs to be performed to optimally guide human trials.
Injection of MNCs proximal to the site of ischemia may provide different outcomes compared with distal injection and
warrants additional study. (J Vasc Surg 2012;56:1669-79.)
Clinical Relevance: Despite advances in surgical and endovascular technique, the options for many patients with critical
limb ischemia remain limited. The injection of bone marrow-derived stem cells into ischemic tissue has been identified as
a potential therapeutic alternative. Trial results have been consistently positive, yet the methods under which cell therapy
is administered remain highly variable. The rationale for our study was to design a murine hind limb ischemia model
capable of testing cell therapy parameters, such as optimal cell population, site of administration, and dose, and to use this
preclinical knowledge to better guide and compare human trials.
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(EPCs) from the peripheral circulation in 1997 trans-
formed the field of stem cell biology and created optimism
for cell-based treatment of critical limb ischemia (CLI).1
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December 20121670 Brenes et aldisease or comorbidities.2 Despite advances in surgical and
endovascular techniques, as well as advances in anesthesia
and critical care, the options for these patients remain
limited, with most ultimately requiring amputation.3-5 At
present, no standard effective treatment strategies are avail-
able for these no-option patients, and it is precisely for these
patients that stem cell therapy holds the potential to create
therapeutic alternatives. Accordingly, the use of bone
marrow-derived stem cells has been identified as a potential
method for inducing therapeutic angiogenesis.6
The publication of the Therapeutic Angiogenesis Using
Cell Transplantation (TACT) trial in 2002was the first report
describing the use of bonemarrow-derivedmononuclear cells
(MNCs) in humans for the treatment of CLI,7 and several
additional studies have been published since using MNCs
derived from bone marrow8-16 or peripheral blood.8,17-25
Recent publications have been generally positive with regard
to improvements in extremity perfusion andmotor function.6
However, the greatest inconsistency in these reports
comes from observed variability in MNC preparation,
culture, and injection. MNC injections have been intra-
muscular8-15,17,19-24 and intra-arterial,9,18 and between
80 and 1000 mL of bone marrow has been used.6,11,26
In addition, the number of MNCs used per patient has
varied widely, from 0.1  109 to as high as 100  109.
The number of injections given is equally variable, with
only one study investigating the relationship between
outcomes and number of injected cells.2,6,14,15,26 Al-
though the value of human studies cannot be underesti-
mated, the differences between these studies, including
variable degrees of ischemia, small patient numbers, and
differing cell therapy techniques, prevent easy interpre-
tation specifying the optimal techniques to use for com-
mon clinical practice.
Animal models are likely to play an important role in
helping to answer some clinical questions to help guide
practice and future trials of cell-based therapy for CLI.
Several different murine hind limb ischemia models have
been used to test angiogenesis via cell-based therapies,
including models of mild and severe ischemia.27 Variations
in the level of occlusion include iliac ligation, femoral
ligation below the branches, femoral ligation with excision
of all branches, and artery and vein stripping, in addition to
operator-dependent variations in technique, including su-
ture ligature vs electrocautery.27,28 Variation in the type of
model used results in different patterns of ischemia and
reperfusion, whereas the level of occlusion does not.29
Among the many uncertainties in therapeutic angio-
genesis are the clinical questions regarding optimal cell
population, site of administration, and cell dose. In this
regard, the rationale for this study was to establish an
acute but reproducible murine model of severe ischemia
that would allow methodic testing of such parameters.
METHODS
All procedures, protocols, and medications used in this
study were approved by the Yale University Institutional
Animal Care and Use Committee. OAnimal model. Unilateral high femoral artery liga-
ion and superficial femoral artery (SFA) excision was
erformed on 6- to 8-week-old male C57BL/6 mice
Jackson Laboratory, Bar Harbor, Me). Intraperitoneal
nesthesia was administered using ketamine (100 mg/
g) and xylazine (5 mg/kg). Mice were positioned in
orsal recumbency with their hind limbs externally ro-
ated. A skin incision was made over the femoral artery
eginning at the inguinal ligament and continued cau-
ally to the popliteal bifurcation. The femoral artery was
solated above the level of the profunda and epigastric
rterial branches, doubly ligated using 7-0 Prolene
Ethicon, Somerville, NJ) suture, and transected. The
FA caudal to the major branch points was dissected,
igated, and excised in its entirety.
Varying concentrations of MNCs (5  105, 1  106,
nd 2 106) or control medium, maintained at a constant
olume of 0.1 mL, were injected distally into the gastroc-
emius muscle (Figs 1-5) or proximally into the semimem-
ranosus muscle (Fig 5) immediately after femoral artery
igation (Fig 1, A). A skin incision only was made on the
ontralateral limb for reference invasive monitoring. The
ncisions were closed, and body temperature was main-
ained with heating pads until the animals recovered from
urgery and were ambulatory.
Antibodies and reagents. Primary antibodies to the
ollowing antigens were obtained as follows: cluster of differ-
ntiation (CD) 31 (Abcam, Cambridge, Mass); vascular en-
othelial growth factor receptor (VEGFR)-2–fluorescein iso-
hiocyanate (FITC), CD11b-FITC, CD34-FITC, CD45–
eridinin-chlorophyll protein, CD133-allophycocyanin, and
D115-phycoerythrin (eBioscience, San Diego, Calif); anti-
ade mounting reagent with 4’,6-diamidino-2-phenylindole,
lexa Fluor 568-conjugated immunoglobulinG, andRoswell
ark Memorial Institute Media 1640 (Life Technologies,
arlsbad, Calif); and histopaque 1077 (Sigma-Aldrich, St.
ouis, Mo).
MNC isolation. Bone marrow was collected from the
ong bones of euthanized C57BL/6 mice. Femurs and tibias
ere harvested, clipped at the metaphyses, flushed with phos-
hate-buffered saline using a 26-gauge needle, and filtered
hrough a 70-m cell strainer. MNCs were isolated by gradi-
nt centrifugation and resuspended inmedium for immediate
ntramuscular injection. Cells isolated from one donor mouse
t an injection concentration of 5 105 could be used to treat
4 to 6 mice.
Fluorescence-activated cell sorting analysis. MNCs
ere isolated from bonemarrow as described and preserved
ith 0.5% paraformaldehyde. Aliquots were created, to
hich fluorescent-conjugated primary antibodies or iso-
ype controls were added. Cells were analyzed in a
ACSCalibur flow cytometer (BD Biosciences, Franklin
akes, NJ). WinMDI 2.9 software (Scripps Research Insti-
ute, La Jolla, Calif) was used to analyze data. Samples were
ormalized to immunoglobulin G isotype controls.
Cutaneous perfusion measurement. Laser Doppler
erfusion imaging (LDPI; Perimed, North Royalton,
hio) was used to measure perfusion of the ligated and
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Volume 56, Number 6 Brenes et al 1671control limbs at predetermined time points. Depilatory
cream was used to remove hind limb hair, and the animals
were kept on a heating pad at 37°C to minimize tempera-
ture variation. Consecutive measurements were obtained
according to the manufacturer’s protocols, and average
hind limb perfusion was determined for an anatomically
defined region of the lateral gastrocnemius and plantar foot
by image analysis using LDPIwin 2.6 software (Perimed).
Calculated perfusion was expressed as a ratio of right (isch-
emic) to left (control) hind limbs.
Functional scoring. Functional scoring was per-
formed using the Tarlov scale,30,31 ischemia scale,31,32 and
modified ischemia scale31 (Table).
Invasive Doppler flow measurement. Blood flow
was measured in some anesthetized animals in the ischemic
leg and the control leg preoperatively, immediately postop-
eratively, and at 1 to 4 weeks after induction of hind limb
ischemia, using the PeriFlux Laser Doppler PerfusionMea-
surement unit with a “deep probe” configuration (Per-
imed).31 Access to the soleus muscle was obtained through
a 3-mm skin incision on each hind limb that was closed after
Fig 1. Methods. A,Modified hind limb ischemia mode
asterisks (*) denote length of superficial femoral artery
arrow). C, D, Expression of bone marrow mononuclea
progenitor cell markers.G,H,Coexpression of mononuc
of differentiation; FSC, fluorophore-conjugated second
receptor. The error bars show the standard error of the mmeasurement. The same incision was used for all measure- fents and was made only for mice having flow measure-
ents and not for any other experiments. This method
llows for reproducible measurements directly in the mus-
le bed, avoiding cutaneous blood flow and impaired
ound healing, and is not significantly temperature-dependent.
lood flow values were expressed as the ratio of ischemic-
o-control leg perfusion.31
Histologic preparation and analysis. At appropriate
ntervals after femoral artery ligation, animals were eutha-
ized. Vessels were flushed with phosphate-buffered saline
nd heparin (250U/kg). Perfusion-fixation was performed
sing 10% neutral buffered formalin solution, and the
ilateral gastrocnemius muscles were removed. Tissue was
mbedded in paraffin, cut into 7-m sections, and stained
ith hematoxylin and eosin for histology. Fiber area and
umber were calculated by averaging the counts of five
eparate fields in four distinct areas in each specimen by a
linded observer using ImageJ software (National Insti-
utes of Health, Bethesda, Md).
Capillary density analysis. Tissue sections were depar-
ffinized and stained using a primary antibody against CD31,
arrow (2) denotes the site of femoral ligation, and the
ion. B, Representative image of digit gangrene (black
(BM-MNC) markers. E, F, Expression of endothelial
ell and endothelial progenitor cell markers.CD, Cluster
ntibody; VEGFR, vascular endothelial growth factorl. The
excis
r cell
lear c
ary aollowed by application of a fluorophore-conjugated second-
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diamidino-2-phenylindole was applied before cover slips were
placed. Capillary density, defined as number of capillaries per
muscle fiber, was counted manually by a blinded observer
using ImageJ software in five different randomized fields per
slide (original magnification,40).
Statistical analysis. Statistical analysis was performed
usingGraphPad Prism 5 (GraphPad Software, La Jolla, Calif).
Results are expressed as the mean  standard error of the
mean. Comparisons between groups were performed using
analysis of variance, with post hoc testing performed with
Bonferroni analysis or unpaired t-tests, as appropriate. Values
of P.05 were considered statistically significant.
RESULTS
MNCs and EPCs are present in bone marrow
isolates. MNCs were isolated using a protocol similar to
Fig 2. Mononulear cell (MNC) treatment (5  105) im
n  20). A, MNC-treated mice showed improved funct
MNC-treated mice had greater improvement of ischemi
differences were observed for the modified ischemia
MNC-treated mice had improved (D) proximal flow (*P
laser Doppler images show improved perfusion in MN
MNC-treated mice at days 7 and 14. P values represent
the standard error of the mean.one used in clinical practice.33 Flow cytometry showed that t0.74%  1.67% of the murine bone marrow cells isolated
ith this protocol were CD45 leukocytes. Further char-
cterization of this isolate found it to be CD115– and
D11b (46.65% 6.41%; Fig 1, C andD). EPC markers
ere found at varying amounts, with high levels of expres-
ion of VEGFR2 (75.55%  6.10%) but lower levels of
D34 (14.29% 1.32%) and CD133 (7.48% 3.10%; Fig
, E and F); cells were most frequently dual-positive for
D45 and VEGFR2 (Fig 1, G and H). These results
uggest that MNCs derived from a clinically used protocol
ave a large number of monocytes with varying quantities
f EPCs.
MNC treatment improves outcomes in the murine
ind limb ischemia model. Hind limb ischemia was in-
uced acutely in mice using common femoral artery liga-
ion and superficial femoral artery excision (Fig 1, A),
roducing reproducible toe gangrene (Fig 1, B). Mice were
es hind limb ischemia (MNC-treated, n  21; control,
outcomes according to Tarlov score (*P  .0004). B,
hown by ischemia score (P  .0002). C, No significant
(P  .4587). Invasive Doppler measurements show
01) and (E) distal flow (*P .0001). F, Representative
eated mice. The arrows show improved perfusion in
ical analysis by analysis of variance. The error bars showprov
ional
a as s
score
 .00
C-tr
statistreated immediately afterward with control vehicle without
s
s
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gastrocnemius muscle. Mice treated with MNCs and con-
trol mice showed equally diminished proximal and distal
flow on day 0 after femoral artery ligation compared with
the contralateral leg (proximal: 0.39 0.02 vs 0.40 0.03
perfusion units [ratio ischemic:control], P  .8305; distal:
0.28 0.01 vs 0.27 0.01 perfusion units [ratio ischemic:
control], P  .6904, t-test).
Over 28 days, MNC-treated mice showed improved
functional outcomes compared with control mice, with
accelerated improvement in the Tarlov score at day 7 (5.43
0.21 vs 4.37 0.23, P .0017, t-test; Fig 2,A). The grade
of ischemia improved in MNC-treated mice using the
ischemia score (P  .0002) but not the modified ischemia
score (P .456; Fig 2, B and C). Mice treated with MNCs
Fig 3. Gastrocnemius muscle histology in mice treated
3). A, Histologic comparison of control (left) and MNC
and eosin; original magnificiation,40).B,MNC-treate
and 28 (*P  .0053). C, MNC-treated mice showe
MNC-treated mice demonstrated higher capillary density
by analysis of variance. The error bars show the standardshowed significantly augmented proximal and distal perfu- .ion, as measured at day 7 with invasive Doppler (proximal
emimembranosus flow: 0.87  0.04 vs 0.73  0.05, P 
0429; distal gastrocnemius flow: 0.61  0.03 vs 0.51 
.02, P .0024, t-test; Fig 2,D and E) or with noninvasive
aser Doppler (Fig 2, F).
Histologic findings correlated with vascular and
unctional outcomes (Fig 3, A). MNC-treated mice
howed increased gastrocnemius muscle fiber area com-
ared with control mice (P  .0053; Fig 3, B). In
ddition, MNC-treated mice showed fewer muscle fibers
er high-power field compared with control mice (P 
0001; Fig 3, C). Angiogenesis was measured in histo-
ogic sections by direct assessment of capillary density; at
ay 14, MNC-treated mice showed increased gastrocne-
ius capillary density compared with control mice (P 
mononuclear cells (MNCs; n  3) and in controls (n 
ed (right) mice over 28 days (stained with hematoxylin
e demonstrated increased muscle fiber area at days 7, 14,
creased number of muscle fibers (*P  .0001). D,
y 14 (*P .0001). P values represent statistical analysis
of the mean.with
-treat
d mic
d de
at da0004, t-test; Fig 3, D). These data show increased
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December 20121674 Brenes et alFig 4. Mononuclear cell (MNC) dose–response (n  4 to 6 per group). A, Quantification of representative laser
Doppler perfusion images showed no differences between MNC-treated groups at day 7 (P  .7501, analysis of
variance [ANOVA]). B,MNC-treated mice show increased perfusion (day 7) compared with control mice (P .0018,
ANOVA); 5 105 and 1 106 MNC groups showed increased distal flow vs control (*P .05, post hoc test; **P
.05 vs other groups).C,No significant differences betweenMNC-treatment groups and control were seen in functional
outcomes (P  .5520, ANOVA). D, Capillary density was increased at day 14 in MNC-treated mice vs control mice
(n  3; P  .0001, ANOVA; *P  .05 vs control, post hoc test; **P  .05 vs control, post hoc test; P  .05 vs each
other, post hoc test). E,Gastrocnemius muscle fiber area was increased at day 14 in MNC-treated mice vs control mice
(P  .0001, ANOVA; *P  .05 vs control, post hoc test; **P  .05 vs control, post hoc test; P  .05 vs each other,
post hoc test). The error bars show the standard error of the mean.
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Volume 56, Number 6 Brenes et al 1675angiogenesis in MNC-treated mice compared with con-
trol mice, consistent with the data showing increased
limb perfusion (Figs 2, B, D, E, and F).
Increased MNC dose affects outcomes. To demon-
strate the relevance of the animal model, we evaluated a
question of clinical significance: Does the number of
MNCs injected make a difference in outcome? Accord-
ingly, dose–response groups were evaluated. MNC-treated
mice received gastrocnemius muscle injections with doses
of 5 105, 1 106, or 2 106 MNCs, with control mice
receiving no cells. Laser Doppler perfusion imaging of the
distal foot on day 7 showed increased perfusion in the
MNC-treatedmice compared with control mice, but without
any significant differences between the treatment groups (P
.7501; Fig 4,A). Quantification, as assessed by invasive Dop-
pler flow imaging, showed all MNC treatment groups (5 
105, 1  106, and 2  106) displayed increased distal flow
compared with control mice (P .0018; Fig 4, B), similar to
the findings with noninvasive laser Doppler (Fig 4, A). The
groups showed no differences in functional scores (Tarlov:
P .5520; ischemia score: P .4444; Fig 4, C).
Despite the lack of gross functional responses with
higher MNC doses, there was evidence of response on the
microscopic level (Fig 4, D and E). At day 14, the MNC-
treated mice demonstrated increased capillary density com-
pared with control mice (P .0001; Fig 4,D). The highest
capillary density was observed in the 1  106 MNC-
treatment group, with no significant difference in capillary
density observed between the 1  106 and 2  106
MNC-treatment groups (P  .05; Fig 4, D).
Histologic evaluation of gastrocnemius muscle fiber area
suggested a correlation between improved gastrocnemius
muscle architecture and treatment with increased MNC con-
centrations. At day 14, all MNC-treated mice showed in-
creased gastrocnemius fiber area compared with control mice
(P  .0001; Fig 4, E). Gastrocnemius fiber area was statisti-
cally increased in the 1  106 and 2  106 MNC-treatment
groups compared with the 5  105 MNC-treatment group
and control mice (P  .05) but without difference between
the 1 106 and 2 106 MNC-treatment groups (P .05).
Similar outcomes were seen between the MNC-treated mice
and control mice in gastrocnemius muscle fiber number, and
groups treated with higher doses of MNCs showed dimin-
ished fiber numbers comparedwith controlmice (P .0002).
These results suggest that increased dose of injected MNC
have effects on the microcirculation but may be inadequate at
the doses examined to affect functional scores or gross perfu-
sion.
Proximal MNC injections influence distal ischemia
outcomes. We also examined another clinical question:
Does a more proximal injection site, proximal to the ischemic
area, affect the response? Treatment groups received 5 105
MNC cells that were injected proximally into the semimem-
branosus muscle (Fig 1,A), whereas control mice received no
cells. No statistically significant differences were observed in
the functional or ischemic scores between the proximally
injected and distally injected mice (Fig 5, A and B). iAt day 7, flow in the proximal muscles was higher in the
NC-treatedmice than in controlmice (P .0041), with no
ifference between proximal and distal injection (P .05; Fig
, C). However, flow in the distal muscles was increased in
oth proximally injected and distally injected mice compared
ith control mice (P .0086), without a difference between
roximal and distal injections (P .05; Fig 5, D).
Similar to these data, the proximally injected MNC-
reated mice showed higher capillary density at day 14 than
ontrol mice (P  .0001) but without any significant
ifferences in capillary density compared with the distally
njected group (P  .05; Fig 5, E).
Histologic evaluation of the gastrocnemius muscle at day
4 demonstrated increased fiber area in MNC-treated mice
han in control mice (P  .0001) and in proximally injected
ice compared with distally injectedmice (P .05; Fig 5, F).
imilarly, gastrocnemius fiber numberwas decreased at day 14
n MNC-treated mice compared with control mice (P 
002), without any significant differences in fiber number
etween proximally injected and distally injected mice (P 
05; Fig 5, G). These data are consistent with stem cell
njections improving the kinetics of recovery from hind limb
schemia, despite the limitations of our mouse model.
ISCUSSION
New clinical studies suggest that stem cell injection for
LI is a valid therapeutic option in selected patients. De-
pite supporting clinical evidence, conflicting clinical pro-
ocols and ignorance regarding stem cell biology have
empered adoption of stem cell therapy in clinical practice.
e describe an easy-to-perform preclinical model to test
ifferent parameters of stem cell therapy. We show that
NC treatment provided a more rapid improvement in
erfusion in this ischemic model, that a dose–response
urve is likely to exist for stem cells, and that the site of stem
ell injection may have functional consequences.
The rationale for this study was to establish an acute
urinemodel of severe ischemia that could accommodate the
esting of several clinical parameters important to clinical trials
f cell therapy. A study demonstrating six different ischemia
odels concluded that simple ligation of the femoral artery at
he level below the deep femoral (profunda) artery is most
uitable for studying chronic mild ischemia.27 This model
esulted in a range from no necrosis to toe necrosis. Many
rticles in the literature use the severe ischemia model, which
onsists of femoral artery ligation with excision of all side
ranches.27,34-40 This model results in severe ischemia with
rofound necrosis, ranging from toe necrosis to autoamputa-
ion of limbs. Stripping the femoral artery from the distal site
f bifurcation of the deep femoral artery to the saphenous
rtery is most suitable for a model of severe ischemia.27 The
eep arterial system remains intact, however, andbloodflow is
edirected through this route.
We believe our model more closely resembles diseases
n humans where arteries are occluded but still present. This
an result in arteriogenesis as well as angiogenesis. We
dopted a variation of the arterial stripping model as well as
nterrupting collateral flow through the deep system by
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December 20121676 Brenes et alFig 5. Comparison of response to proximal vs distal mononuclear cell (MNC) injection (n  21) vs control (n  6).
A, Functional measurements with the Tarlov scale (day 7) showed no difference between control and MNC-treated
groups (P .9821).B, Functional measurements with the ischemia scale (day 7) showed no difference between groups
(P  .6594). C, Increased semimembranosus flow with MNC-treated mice (P  .0041, analysis of variance
[ANOVA]); there was no significant difference in flow between proximal and distal treatment (P  .05, post hoc test;
*P .05 vs control, post hoc test).D,Distal flow was increased in proximally and distally treated mice vs control (P
.0086, ANOVA). There was no significant difference in flow between proximal and distal MNC treatment (P  .05,
post hoc test; *P  .05 vs control, post hoc test, n  3). E, MNC-treated mice showed increased capillary density
compared with control and baseline (P  .0001, ANOVA); there was no significant difference in capillary density
between proximally and distally treated mice (P  .05, post hoc test; *P  .05 vs control, post hoc test, n  3). F,
MNC-treated mice showed increased gastrocnemius muscle fiber area compared with control mice (P  .0001,
ANOVA). The difference between proximal and distal injection was significant (P  .05, post hoc test; *P  .05 vs
control, post hoc test, n 3.)G,MNC-treated mice showed decreased gastrocnemius muscle fiber number compared
with control mice (P  .002, ANOVA); the difference between proximal and distal injection was not significant (P 
.05, post hoc test; *P  .05 vs control, post hoc test, n  3).
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Volume 56, Number 6 Brenes et al 1677ligation above the branches. Through the use of this mod-
ified model, we were able to consistently achieve distal hind
limb tissue necrosis and thus more accurately represent
chronic manifestations of atherosclerotic disease (Fig 1, B).
However, small technical variations in this ischemia model
have physiologic consequences.29 With excision of all
branches, arteriogenesis cannot be studied because all pre-
existing connections of arterioles to the vascular tree are
disrupted and cannot be repaired.
The lack of an in-depth understanding regarding EPCs
and their lineage continues to be problematic. Clinical
observations that cell therapies based on whole bone mar-
row appear to be more successful than isolated cell sub-
populations6,24 have led to the idea that several different
bone marrow cell types, all sharing a common monocytic
phenotype, are necessary for successful angiogenesis. Clin-
ical studies have traditionally relied on the use of density
gradient centrifugation to isolate MNC fractions from
whole bone marrow.41 Therefore, we used this method to
isolate the murineMNCs to be tested in this study. Human
studies have documented the composition of the clinically
used bone marrow-derived MNC isolate and have found a
heterogenous population of cell types that includes hema-
topoietic stem cells (CD34), MNCs (CD14, CD11b,
CD115), and EPCs (CD133, VEGFR2).41,42 Using
C57BL/6 bone marrow, we were able to closely replicate
Table. Functional scoring
Score Description
Tarlov score
0 No movement
1 Barely perceptible movement, non–
weight-bearing
2 Frequent movement, non–weight-
bearing
3 Supports weight, partial weight-
bearing
4 Walks with mild deficit
5 Normal but slow walking
6 Full and fast walking
Ischemia score
0 Autoamputation half lower limb
1 Gangrenous tissue half foot
2 Gangrenous tissue half foot, with
lower limb muscle necrosis
3 Gangrenous tissue half foot,
without lower limb muscle
necrosis
4 Pale foot or gait abnormalities
5 Normal
Modified ischemia score
0 Autoamputation of leg
1 Leg necrosis
2 Foot necrosis
3 Discoloration of 2 toes
4 Discoloration of 1 toe
5 Discoloration of 2 nails
6 Discoloration of 1 nail
7 No necrosisclinical cell therapy marrow isolates. Analysis of our marrow msolate found it was primarily mononuclear in composition
CD45, CD11b), with elimination of granulocytes
chieved through gradient centrifugation. Similar to clini-
al studies, we found varying numbers of EPCs (CD34,
D133, VEGFR2) as well as colocalization of the
eukocyte-common antigen CD45 with progenitor cell
arkers (CD34, CD133, VEGFR2). The ability to
losely replicate human cell therapy using C57BL/6 bone
arrow enhances the clinical utility of this mouse model.
Our results are similar to those reported in several
linical trials.7,8,10,11,43 We observed improvements in
unction and in limb perfusion with MNC treatment (Fig
), as well as augmented muscle fiber regeneration with
vidence of angiogenesis (Fig 3). In previous reports, the
umber of injected MNCs used to treat CLI has been
ariable, and interestingly, positive effects on perfusion have
een observed even when low cell numbers were used.6 Only
ne study to date has attempted to establish an association
etween clinical response and cell number; the authors ob-
erved a correlation between the number of CD34 cells
njected and improvements in ankle-brachial index and con-
luded that the number of injectedCD34 cells was a primary
actor influencing the clinical efficacy of cell therapy.14 Our
ndings show a similar correlation, with the 5  105 MNC-
reatment group showing improved flow compared with con-
rol mice and the higher 1  106 MNC-treatment group
howing improved flow over the control group and the 5 
05MNC-treatment group (Fig 4). This positive correlation,
owever, appears to plateau at a certain cell number, perhaps
econdary to a heightened inflammatory response that inter-
eres with the angiogenic potential of the EPCs, although the
xact mechanism is unclear.
Clinical trials using intramuscular and intravascular in-
ections, or a combination of both, have produced favor-
ble results; however, intramuscular injection into the gas-
rocnemius muscle has been the preferred application in
ost trials.7,44-46 In our study, more proximally injected
NCs showed similar increase in muscle flow and capillary
ensity compared with the more distal injection sites (Fig
). Interestingly, proximal injection did result in increased
ignificantly improved muscle area compared with control
nd distal injection (Fig 5, F); however, there was no overall
ncrease in limb ischemia or function (Fig 5, A and B). We
herefore believe that more proximal injection of MNCs
as the potential for greater therapeutic effect and that the
umbers of MNCs likely need to be increased to achieve
reater functional outcomes. This may be tempered by the
lateau in effect with increased doses of cells (Fig 4),
uggesting that cell dose and injection location need to be
ptimized simultaneously.
Although we believe that our model of murine hind
imb ischemia has clinical value, we likewise recognize its
imitations. Despite the added modification of total SFA
xcision, this model continues to be acute in nature. In
ddition, without additional treatment, C57BL/6 mice
pontaneously regain near-maximal flow within several
eeks after ligation. This quick recovery from ischemia
akes it more difficult to quantify and observe subtle flow
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precisely this inherent ability for spontaneous angiogenesis
that may mask improvements in some of our treatment
groups. Other improvements that could be made to our
model include use of animal models of disease, such as
apolipoprotein E-knockout mice, use of aged animals to
mimic aged human patients, and use of other mouse strains
that have different features of human disease.31
The mouse demonstrates spontaneous recovery from
hind limb ischemia, limiting the ability to discriminate
between changes in the final end point and, thus, the ability
to measure gross changes in tester parameters. However,
we believe our model shows that cellular therapy provides a
kinetic advantage, with faster recovery from ischemia with
parameters measured between 7 and 14 days. Finally, ex
vivo treatment of isolated MNCs with cell culture condi-
tions or drugs, such as statins or growth factors, may mimic
other clinical protocols used in some trials.
CONCLUSIONS
Our study shows that high femoral ligation with com-
plete excision of the SFA is a reproducible model of hind
limb ischemia in C57BL/6 mice. Similar to human trials,
injection of MNCs into murine ischemic limbs improves
vascular and functional outcomes. Our data suggest that
cell number, type, and location of injection can be opti-
mized. As such, it is likely that preclinical animal models
will continue to serve an important role in comparing
factors of clinical utility.
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Dr Darwin Eton (Chicago, Ill): How do you know the cells
are still there 24 hours or 48 hours after injection? Is this a cell
therapy, or is it actually a drug delivery system where the cells get
into the tissue, lyse, and release all the cytokines into the tissue?
How many mice were there in each group?
DrRobertA.Brenes.DrEton, thank you for your questions. In
our study, we did not evaluate if the cells are present 24 to 48 hours
after injection; therefore, I amunable to comment on this.We also did
not evaluate if it is the effector cells or the cytokines released into the
tissue that lead to angiogenesis. However, we believe it may be a
combination of themononuclear cells, endothelial progenitor cells, as
well as the cytokines that all contribute to the angiogenesis seen. In
our primary experiment,wehad ann value of 20mice,with a fewmice
removed at each time point for histological analysis.his is the acute limb ischemia, not the chronic limb ischemia.
owever, the chronic limb ischemia model can be made and
ctually has been utilized by waiting for 4 weeks or 6 after the initial
urgery before starting the treatment. Is this model as durable to
ait like 4 or 6 weeks to create chronic limb ischemia?
Dr Brenes. Dr Yamanouchi, thank you for your comments.
e recognize that our model, as well as others described in the
iterature, are acute models of limb ischemia. C57BL/6 mice
egain their flow spontaneously without cell injection by 4 to 6
eeks post ligation. Therefore, one must study the treatment
odality early after inducing ischemia to see maximal effect. Inter-
stingly, our lab has shown that aged mice have a delayed sponta-
eous recovery to flow as well as functional score. We believe these
ice may be a better model to test cell intervention in more of a
chronic” setting with delayed injections.
